Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3b Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of an Adjuvanted Chikungunya Virus Virus-like Particle (CHIKV VLP) Vaccine for the Prevention of Chikungunya Disease in Adolescents (12 to <18 Years) and Adults (≥18 Years)

NCT07467707 is registered in ClinicalTrials.gov with Bavarian Nordic as lead sponsor.

NCT NCT07467707
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07467707 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3b Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of an Adjuvanted Chikungunya Virus Virus-like Particle (CHIKV VLP) Vaccine for the Prevention of Chikungunya Disease in Adolescents (12 to <18 Years) and Adults (≥18 Years)
Lead sponsor
Bavarian Nordic
Phase
Phase 3
Overall status
Recruiting
Start date
May 26, 2026
Completion date
May 31, 2030
Enrollment
6,144 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

chikungunya virus